Dermapharm Holding SE represents a set of core values and a corporate philosophy that defines its operations. The company strives for excellence through continuous innovation and development of high-quality pharmaceutical products. Dermapharm Holding values integrity, reliability, and responsibility towards its customers, shareholders, employees, and partners. With a focus on sustainability and social responsibility, the company is committed to contributing to the well-being of society and the environment. By combining expertise, entrepreneurial vision, and a customer-centric approach, Dermapharm Holding SE aims to deliver exceptional healthcare solutions while fostering long-term success and growth.

Dermapharm Holding SE, a renowned pharmaceutical company, has a widespread presence primarily in Germany. As a leading player in the German market, Dermapharm has established a strong foothold, catering to the healthcare needs of millions of people across the country. With its headquarters located in Grünwald, Germany, Dermapharm focuses on developing, manufacturing, and distributing various pharmaceutical products, including both prescription and over-the-counter medications. Leveraging its extensive network and expertise, Dermapharm continues to expand its reach beyond Germany, aiming to broaden its presence and deliver high-quality pharmaceutical solutions to customers in other European countries and regions as well.

Dermapharm Holding SE, a renowned pharmaceutical company, has accomplished several notable milestones. The company has successfully expanded its product portfolio, offering a diverse range of high-quality pharmaceuticals and health-related products. Dermapharm aims at driving growth and innovation through strategic acquisitions and partnerships, expanding its market presence both nationally and internationally. The company has consistently achieved robust financial results, demonstrating its strong performance and market resilience. Dermapharm Holding SE has also demonstrated its commitment to sustainability, implementing environmentally friendly practices throughout its operations. Through its continuous dedication to excellence, Dermapharm Holding SE has positioned itself as a leading player in the pharmaceutical industry.

Dermapharm Holding SE is a German pharmaceutical company that specializes in the development and production of various medical products. Founded in 1991, Dermapharm has grown to become one of the leading manufacturers of pharmaceuticals in Germany. The company offers a broad portfolio of prescription and over-the-counter drugs, as well as dietary supplements and herbal medicines. With a strong focus on research and development, Dermapharm aims to continually innovate and provide effective solutions for various therapeutic areas. With its vast experience and high-quality standards, Dermapharm Holding SE has established itself as a trusted name in the pharmaceutical industry.

The main competitors of Dermapharm Holding SE in the market are prominent pharmaceutical companies such as Hexal AG, Stada Arzneimittel AG, and Dr. Reddy's Laboratories Ltd. These competitors engage in similar activities in the pharmaceutical industry and present a significant challenge to Dermapharm Holding SE. Their presence drives competition, fostering innovation and improving product quality. As a leading stock in the industry, Dermapharm Holding SE consistently adapts its strategies to stay ahead of its competitors and deliver value to its shareholders.

Dermapharm Holding SE is primarily active in the pharmaceutical industry.

The business model of Dermapharm Holding SE revolves around the development, production, and distribution of pharmaceutical products. As a leading manufacturer of both branded and generic medications, Dermapharm focuses on a diverse range of therapeutic areas, including dermatology, respiratory diseases, and women's health. The company aims to provide high-quality pharmaceutical solutions to patients and healthcare professionals worldwide. By investing in research and development, Dermapharm continuously innovates its product portfolio to address evolving market demands. With a strong distribution network and strategic partnerships, Dermapharm ensures the availability and accessibility of its pharmaceuticals, contributing to the health and well-being of individuals globally.

Dermapharm Holding의 P/E 비율은 16.89입니다.

Dermapharm Holding의 P/S 비율은 1.73입니다.

Dermapharm Holding에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Dermapharm Holding 매출은 1.25 조. EUR입니다.

예상되는 Dermapharm Holding 이익은 127.68 백만 EUR입니다.

Dermapharm Holding SE is a leading company in the pharmaceutical industry that manufactures and distributes prescription and over-the-counter branded products, generics, and specialty medicines. The company offers a wide range of more than 2500 products, providing innovative solutions for various therapy areas such as dermatology, gynecology, neurology, pain management, urology, and more. The business model of Dermapharm is based on four core areas: 1. Branded products: Dermapharm has developed an extensive portfolio of branded products used in various therapy areas. Some of the best-known ones include Betadona® for disinfection of the skin and mucous membranes, Excipial® for the care of dry, cracked skin, and Allpresan® for the treatment of foot problems. The company is constantly searching for new innovative product ideas and regularly invests in research and development. 2. Generics: Dermapharm also produces and distributes a wide range of generics. These are typically much cheaper than branded products, providing customers with affordable access to important medicines. By manufacturing generics, the company also contributes to making healthcare more accessible for all. 3. Development of specialty medicines: Dermapharm specializes in the development of specialty medicines for niche indications. This includes preparations for the treatment of rare diseases or medications adapted for specific patient groups. Through its focus on these niche markets, the company has built a strong position and created a unique selling proposition. 4. International expansion: In addition to the German market, Dermapharm is also present in other European countries and plans to expand its business globally. The company focuses on targeted expansion and has already formed strategic partnerships in some countries. Overall, Dermapharm's business model is based on a combination of innovative products, high manufacturing expertise, and a strong distribution network. Digitalization also plays an important role, with the company investing in the use of modern technologies to optimize its business processes and create new digital business models. In summary, Dermapharm's business model offers customers access to a wide range of medicines from various therapy areas. The company aims to expand its market share and develop innovative products for the future.

Dermapharm Holding은(는) 연간 1번의 배당을 통해 2.17 EUR의 배당금을 지급합니다.

Dermapharm Holding는 연간 1번의 배당금을 지급합니다.

Dermapharm Holding의 ISIN은 DE000A2GS5D8입니다.

Dermapharm Holding의 WKN은 A2GS5D입니다.

Dermapharm Holding의 티커는 DMP.DE입니다.

지난 12개월 동안 Dermapharm Holding은(는) 1.05 EUR 의 배당금을 지급했습니다. 이는 약 2.62 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Dermapharm Holding은(는) 1.16 EUR의 배당금을 지급할 것으로 예상됩니다.

Dermapharm Holding의 현재 배당 수익률은 2.62 %입니다.

Dermapharm Holding은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Dermapharm Holding은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 1.16 EUR의 배당금이 예상됩니다. 이는 배당수익률 2.9 %에 해당합니다.

Dermapharm Holding은 '건강' 섹터에 속합니다.

Dermapharm Holding의 마지막 배당금을 0.88 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Dermapharm Holding는 1.05 EUR를 배당금으로 지급했습니다.

Dermapharm Holding의 배당금은 EUR에 지급됩니다.